Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of respiratory disorders such as asthma and COPD
3.2.1.2 Ongoing R&D efforts and new product approvals
3.2.1.3 Off-label use of bronchodilators
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug-class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Beta-adrenergic bronchodilators
5.3 Anticholinergic bronchodilators
5.4 Xanthine derivatives
5.5 Other drug classes
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Inhaled
6.5 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Asthma
7.3 Chronic obstructive pulmonary disease (COPD)
7.4 Other application
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals
9.3 Specialty clinics
9.4 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AstraZeneca
11.2 Boehringer Ingelheim International GmbH
11.3 Cipla Inc.
11.4 GlaxoSmithKline plc
11.5 Glenmark Pharmaceuticals Limited
11.6 Innoviva
11.7 Medline Plus
11.8 Merck & Co.,
11.9 Mylan N.V.
11.10 Novartis AG
11.11 Sun Pharmaceutical Industries Ltd
11.12 Teva Pharmaceutical Industries Ltd
